Enter your medication and last dose date. Get a personalised clinical timeline of what to expect — and a specific action plan for your phase.
Built by an NHS A&E doctor with a decade in metabolic medicine. Not generic wellness content. Clinical depth, plain language.
Clinical appointments via CQC-registered Sutton Medical Consulting
Educational tool. Not personal medical advice. If you have diabetes, are pregnant, or feel unwell — speak to your clinician.
"What you're navigating right now is one of the least well-supported transitions in modern medicine. The prescription is easy to get. The off-ramp isn't. This report is designed to change that — to give you the clinical framework that most patients never receive."
Dr Dan Reardon MB ChB, BSc (Anatomy), MSc (Mental Health)A 60-minute Exit Strategy Review gives you a medically defensible written plan — specific to your history, your body, and your life. Not a protocol. A plan.
Via CQC-registered Sutton Medical Consulting · In-person or video
Private GLP-1 clinics are built to start treatment. Almost none are built to plan what happens when it stops. This tool fills that gap.
GLP-1 drugs suppress appetite pharmacologically. When the drug clears, appetite returns. Understanding when and why it happens is the first step to managing it.
The STEP 4 and SURMOUNT-4 trials both show weight regain accelerates in the first 3–6 months. This is when a plan matters most — and when most people have none.
Appetite drive is a biological signal. Fighting it with willpower alone is a weak strategy. Building the right environment and routine before it returns is the correct approach.
GLP-1 drugs cause both fat and muscle loss. Stopping without a strength protocol accelerates further muscle loss — making weight regain faster and harder to reverse.
A single clinician-led exit review — covering tapering, monitoring, maintenance, and contingency — significantly changes the probability of maintaining results.
The STEP 4 trial — published in the New England Journal of Medicine in 2022 — followed patients who stopped semaglutide after 20 weeks. Within 12 months of stopping, participants had regained an average of two thirds of their lost weight. Cardiometabolic improvements reversed in parallel.
SURMOUNT-4 (JAMA, 2024) showed a similar pattern with tirzepatide. Participants who switched to placebo regained significant weight while those who continued did not.
This is not a failure of the medication. It is what happens when a pharmacological support is removed without anything in place to replace what it was doing. Appetite returns. Food noise returns. The old patterns return.
The question is not whether this will happen. The question is what is in place to manage it when it does.
This tool exists because the exit problem is real, well-evidenced, and almost entirely ignored by the systems that created it. Private GLP-1 prescribing has grown enormously. Exit planning has not kept pace.
I work in NHS emergency medicine and run a private practice focused on deprescribing — GLP-1s, SSRIs, PPIs, statins, antihypertensives. What I see in both settings is the same: patients who were well-supported starting treatment and left to figure out the exit on their own.
This tool is the free version of the clinical framework I use in practice. If you want the full version — with your history, your results, and a written plan specific to you — that's what the Exit Strategy Review is for.
Book your GLP-1 Exit Strategy Review and leave with a written plan for what comes next — specific to you, not a generic protocol.
Book your Exit Strategy Review — £395Via CQC-registered Sutton Medical Consulting · Sutton Coldfield · Video available UK-wide